Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 6/2008

Open Access 01-12-2008 | Research

Recombinant human activated protein C ameliorates oleic acid-induced lung injury in awake sheep

Authors: Kristine Waerhaug, Mikhail Y Kirov, Vsevolod V Kuzkov, Vladimir N Kuklin, Lars J Bjertnaes

Published in: Critical Care | Issue 6/2008

Login to get access

Abstract

Introduction

Acute lung injury (ALI) may arise both after sepsis and non-septic inflammatory conditions and is often associated with the release of fatty acids, including oleic acid (OA). Infusion of OA has been used extensively to mimic ALI. Recent research has revealed that intravenously administered recombinant human activated protein C (rhAPC) is able to counteract ALI. Our aim was to find out whether rhAPC dampens OA-induced ALI in sheep.

Methods

Twenty-two yearling sheep underwent instrumentation. After 2 days of recovery, animals were randomly assigned to one of three groups: (a) an OA+rhAPC group (n = 8) receiving OA 0.06 mL/kg infused over the course of 30 minutes in parallel with an intravenous infusion of rhAPC 24 mg/kg per hour over the course of 2 hours, (b) an OA group (n = 8) receiving OA as above, or (c) a sham-operated group (n = 6). After 2 hours, sheep were sacrificed. Hemodynamics was assessed by catheters in the pulmonary artery and the aorta, and extravascular lung water index (EVLWI) was determined with the single transpulmonary thermodilution technique. Gas exchange was evaluated at baseline and at cessation of the experiment. Data were analyzed by analysis of variance; a P value of less than 0.05 was regarded as statistically significant.

Results

OA induced profound hypoxemia, increased right atrial and pulmonary artery pressures and EVLWI markedly, and decreased cardiac index. rhAPC counteracted the OA-induced changes in EVLWI and arterial oxygenation and reduced the OA-induced increments in right atrial and pulmonary artery pressures.

Conclusions

In ovine OA-induced lung injury, rhAPC dampens the increase in pulmonary artery pressure and counteracts the development of lung edema and the derangement of arterial oxygenation.
Appendix
Available only for authorised users
Literature
1.
Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med. 2000, 342: 1301-1308. 10.1056/NEJM200005043421801.
2.
Quinlan GJ, Lamb NJ, Evans TW, Gutteridge JM: Plasma fatty acid changes and increased lipid peroxidation in patients with adult respiratory distress syndrome. Crit Care Med. 1996, 24: 241-246. 10.1097/00003246-199602000-00010.CrossRefPubMed
3.
Baughman RP, Stein E, MacGee J, Rashkin M, Sahebjami H: Changes in fatty acids in phospholipids of the bronchoalveolar fluid in bacterial pneumonia and in adult respiratory distress syndrome. Clin Chem. 1984, 30: 521-523.PubMed
4.
Bursten SL, Federighi DA, Parsons P, Harris WE, Abraham E, Moore EE, Moore FA, Bianco JA, Singer JW, Repine JE: An increase in serum C18 unsaturated free fatty acids as a predictor of the development of acute respiratory distress syndrome. Crit Care Med. 1996, 24: 1129-1136. 10.1097/00003246-199607000-00011.CrossRefPubMed
5.
Schuster DP: ARDS: clinical lessons from the oleic acid model of acute lung injury. Am J Respir Crit Care Med. 1994, 149: 245-260.CrossRefPubMed
6.
Fulcher CA, Gardiner JE, Griffin JH, Zimmerman TS: Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V. Blood. 1984, 63: 486-489.PubMed
7.
Walker FJ, Sexton PW, Esmon CT: The inhibition of blood coagulation by activated Protein C through the selective inactivation of activated Factor V. Biochim Biophys Acta. 1979, 571: 333-342.CrossRefPubMed
8.
Bilbault P, Lavaux T, Launoy A, Gaub MP, Meyer N, Oudet P, Pottecher T, Jaeger A, Schneider F: Influence of drotrecogin alpha (activated) infusion on the variation of Bax/Bcl-2 and Bax/Bcl-xl ratios in circulating mononuclear cells: a cohort study in septic shock patients. Crit Care Med. 2007, 35: 69-75. 10.1097/01.CCM.0000251133.26979.F4.CrossRefPubMed
9.
Feistritzer C, Riewald M: Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood. 2005, 105: 3178-3184. 10.1182/blood-2004-10-3985.CrossRefPubMed
10.
Shires GT, Fisher O, Murphy P, Williams S, Barber A, Johnson G, Davis B, Pahulu S: Recombinant activated protein C induces dose-dependent changes in inflammatory mediators, tissue damage, and apoptosis in in vivo rat model of sepsis. Surg Infect (Larchmt). 2007, 8: 377-386. 10.1089/sur.2006.082.CrossRef
11.
White B, Schmidt M, Murphy C, Livingstone W, O'Toole D, Lawler M, O'Neill L, Kelleher D, Schwarz HP, Smith OP: Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br J Haematol. 2000, 110: 130-134. 10.1046/j.1365-2141.2000.02128.x.CrossRefPubMed
12.
Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001, 344: 699-709. 10.1056/NEJM200103083441001.CrossRefPubMed
13.
Dhainaut JF, Laterre PF, Janes JM, Bernard GR, Artigas A, Bakker J, Riess H, Basson BR, Charpentier J, Utterback BG, Vincent JL: Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med. 2003, 29: 894-903.PubMed
14.
Shorr AF, Bernard GR, Dhainaut JF, Russell JR, Macias WL, Nelson DR, Sundin DP: Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome. Crit Care. 2006, 10: R92-10.1186/cc4946.PubMedCentralCrossRefPubMed
15.
Matthay MA, Ware LB: Plasma protein C levels in patients with acute lung injury: prognostic significance. Crit Care Med. 2004, 32: S229-S232. 10.1097/01.CCM.0000126121.56990.D3.CrossRefPubMed
16.
Maybauer MO, Maybauer DM, Fraser JF, Traber LD, Westphal M, Enkhbaatar P, Cox RA, Huda R, Hawkins HK, Morita N, Murakami K, Mizutani A, Herndon DN, Traber DL: Recombinant human activated protein C improves pulmonary function in ovine acute lung injury resulting from smoke inhalation and sepsis. Crit Care Med. 2006, 34: 2432-2438. 10.1097/01.CCM.0000230384.61350.FA.CrossRefPubMed
17.
Wang Z, Su F, Rogiers P, Vincent JL: Beneficial effects of recombinant human activated protein C in a ewe model of septic shock. Crit Care Med. 2007, 35: 2594-2600.CrossRefPubMed
18.
Waerhaug K, Kuklin VN, Kirov MY, Sovershaev MA, Langbakk B, Ingebretsen OC, Ytrehus K, Bjertnaes LJ: Recombinant human activated protein C attenuates endotoxin-induced lung injury in awake sheep. Crit Care. 2008, 12: R104-10.1186/cc6985.PubMedCentralCrossRefPubMed
19.
Nielsen JS, Larsson A, Rix T, Nyboe R, Gjedsted J, Krog J, Ledet T, Tonnesen E: The effect of activated protein C on plasma cytokine levels in a porcine model of acute endotoxemia. Intensive Care Med. 2007, 33: 1085-1093. 10.1007/s00134-007-0631-1.CrossRefPubMed
20.
Richard JC, Bregeon F, Leray V, Le Bars D, Costes N, Tourvieille C, Lavenne F, Devouassoux-Shisheboran M, Gimenez G, Guerin C: Effect of activated protein C on pulmonary blood flow and cytokine production in experimental acute lung injury. Intensive Care Med. 2007, 33: 2199-2206. 10.1007/s00134-007-0782-0.CrossRefPubMed
21.
Robriquet L, Collet F, Tournoys A, Prangère T, Nevière R, Fourrier F, Guery BP: Intravenous administration of activated protein C in Pseudomonas-induced lung injury: impact on lung fluid balance and the inflammatory response. Respir Res. 2006, 7: 41-10.1186/1465-9921-7-41.PubMedCentralCrossRefPubMed
22.
Liu KD, Levitt J, Zhuo H, Kallet RH, Brady S, Steingrub J, Tidswell M, Siegel MD, Soto G, Peterson MW, Chesnutt MS, Phillips C, Weinacker A, Thompson BT, Eisner MD, Matthay MA: Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med. 2008, 178: 618-623. 10.1164/rccm.200803-419OC.PubMedCentralCrossRefPubMed
23.
Kuklin VN, Kirov MY, Evgenov OV, Sovershaev MA, Sjoberg J, Kirova SS, Bjertnaes LJ: Novel endothelin receptor antagonist attenuates endotoxin-induced lung injury in sheep. Crit Care Med. 2004, 32: 766-773. 10.1097/01.CCM.0000114575.08269.F6.CrossRefPubMed
24.
Bjertnaes LJ, Koizumi T, Newman JH: Inhaled nitric oxide reduces lung fluid filtration after endotoxin in awake sheep. Am J Respir Crit Care Med. 1998, 158: 1416-1423.CrossRefPubMed
25.
Neumann P, Hedenstierna G: Ventilation-perfusion distributions in different porcine lung injury models. Acta Anaesthesiol Scand. 2001, 45: 78-86. 10.1034/j.1399-6576.2001.450113.x.CrossRefPubMed
26.
Sakka SG, Ruhl CC, Pfeiffer UJ, Beale R, McLuckie A, Reinhart K, Meier-Hellmann A: Assessment of cardiac preload and extravascular lung water by single transpulmonary thermodilution. Intensive Care Med. 2000, 26: 180-187. 10.1007/s001340050043.CrossRefPubMed
27.
Kirov MY, Kuzkov VV, Kuklin VN, Waerhaug K, Bjertnaes LJ: Extravascular lung water assessed by transpulmonary single thermodilution and postmortem gravimetry in sheep. Crit Care. 2004, 8: R451-10.1186/cc2974.PubMedCentralCrossRefPubMed
28.
Katzenelson R, Perel A, Berkenstadt H, Preisman S, Kogan S, Sternik L, Segal E: Accuracy of transpulmonary thermodilution versus gravimetric measurement of extravascular lung water. Crit Care Med. 2004, 32: 1550-1554. 10.1097/01.CCM.0000130995.18334.8B.CrossRefPubMed
29.
Abraham E, Carmody A, Shenkar R, Arcaroli J: Neutrophils as early immunologic effectors in hemorrhage- or endotoxemia-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2000, 279: L1137-L1145.PubMed
30.
Terada LS, Dormish JJ, Shanley PF, Leff JA, Anderson BO, Repine JE: Circulating xanthine oxidase mediates lung neutrophil sequestration after intestinal ischemia-reperfusion. Am J Physiol. 1992, 263: L394-L401.PubMed
31.
Nill MR, Oberyszyn TM, Ross MS, Oberyszyn AS, Robertson FM: Temporal sequence of pulmonary cytokine gene expression in response to endotoxin in C3H/HeN endotoxin-sensitive and C3H/HeJ endotoxin-resistant mice. J Leukoc Biol. 1995, 58: 563-574.PubMed
32.
Abraham E: Neutrophils and acute lung injury. Crit Care Med. 2003, 31: S195-S199. 10.1097/01.CCM.0000057843.47705.E8.CrossRefPubMed
33.
Brueckmann M, Hoffmann U, De Rossi L, Weiler HM, Liebe V, Lang S, Kaden JJ, Borggrefe M, Haase KK, Huhle G: Activated protein C inhibits the release of macrophage inflammatory protein-1-alpha from THP-1 cells and from human monocytes. Cytokine. 2004, 26: 106-113. 10.1016/j.cyto.2004.01.004.CrossRefPubMed
34.
Nick JA, Coldren CD, Geraci MW, Poch KR, Fouty BW, O'Brien J, Gruber M, Zarini S, Murphy RC, Kuhn K, Richter D, Kast KR, Abraham E: Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood. 2004, 104: 3878-3885. 10.1182/blood-2004-06-2140.CrossRefPubMed
35.
Stephenson DA, Toltl LJ, Beaudin S, Liaw PC: Modulation of monocyte function by activated protein C, a natural anticoagulant. J Immunol. 2006, 177: 2115-2122.CrossRefPubMed
36.
Sturn DH, Kaneider NC, Feistritzer C, Djanani A, Fukudome K, Wiedermann CJ: Expression and function of the endothelial protein C receptor in human neutrophils. Blood. 2003, 102: 1499-1505. 10.1182/blood-2002-12-3880.CrossRefPubMed
37.
Hill LL, Chen DL, Kozlowski J, Schuster DP: Neutrophils and neutrophil products do not mediate pulmonary hemodynamic effects of endotoxin on oleic acid-induced lung injury. Anesth Analg. 2004, 98: 452-457. 10.1213/01.ANE.0000097167.39112.A3. tableCrossRefPubMed
38.
Hofman WF, Ehrhart IC: Permeability edema in dog lung depleted of blood components. J Appl Physiol. 1984, 57: 147-153.PubMed
39.
Wang L, Zhu DM, Su X, Bai CX, Ware LB, Matthay MA: Acute cardiopulmonary effects of a dual-endothelin receptor antagonist on oleic acid-induced pulmonary arterial hypertension in dogs. Exp Lung Res. 2004, 30: 31-42.CrossRefPubMed
40.
Furue S, Kuwabara K, Mikawa K, Nishina K, Shiga M, Maekawa N, Ueno M, Chikazawa Y, Ono T, Hori Y, Matsukawa A, Yoshinaga M, Obara H: Crucial role of group IIA phospholipase A(2) in oleic acid-induced acute lung injury in rabbits. Am J Respir Crit Care Med. 1999, 160: 1292-1302.CrossRefPubMed
41.
Goff CD, Corbin RS, Theiss SD, Frierson HF, Cephas GA, Tribble CG, Kron IL, Young JS: Postinjury thromboxane receptor blockade ameliorates acute lung injury. Ann Thorac Surg. 1997, 64: 826-829. 10.1016/S0003-4975(97)00490-6.CrossRefPubMed
42.
Ishitsuka Y, Moriuchi H, Hatamoto K, Yang C, Takase J, Golbidi S, Irikura M, Irie T: Involvement of thromboxane A2 (TXA2) in the early stages of oleic acid-induced lung injury and the preventive effect of ozagrel, a TXA2 synthase inhibitor, in guinea-pigs. J Pharm Pharmacol. 2004, 56: 513-520. 10.1211/0022357023150.CrossRefPubMed
43.
Rostagno C, Gensini GF, Boncinelli S, Marsili M, Castellani S, Lorenzi P, Merciai V, Linden M, Chelucci GL, Cresci F: The prominent role of thromboxane A2 formation on early pulmonary hypertension induced by oleic acid administration in sheep. Thromb Res. 1990, 58: 35-45. 10.1016/0049-3848(90)90241-4.CrossRefPubMed
44.
Thies SD, Corbin RS, Goff CD, Binns OA, Buchanan SA, Shockey KS, Frierson HF, Young JS, Tribble CG, Kron IL: Thromboxane receptor blockade improves oxygenation in an experimental model of acute lung injury. Ann Thorac Surg. 1996, 61: 1453-1457. 10.1016/0003-4975(96)00077-X.CrossRefPubMed
45.
Menschikowski M, Hagelgans A, Hempel U, Lattke P, Ismailov I, Siegert G: On interaction of activated protein C with human aortic smooth muscle cells attenuating the secretory group IIA phospholipase A(2) expression. Thromb Res. 2008, 122: 69-76. 10.1016/j.thromres.2007.08.015.CrossRefPubMed
46.
Brueckmann M, Horn S, Lang S, Fukudome K, Schulze NA, Hoffmann U, Kaden JJ, Borggrefe M, Haase KK, Huhle G: Recombinant human activated protein C upregulates cyclooxygenase-2 expression in endothelial cells via binding to endothelial cell protein C receptor and activation of protease-activated receptor-1. Thromb Haemost. 2005, 93: 743-750.PubMed
47.
He X, Han B, Mura M, Xia S, Wang S, Ma T, Liu M, Liu Z: Angiotensin-converting enzyme inhibitor captopril prevents oleic acid-induced severe acute lung injury in rats. Shock. 2007, 28: 106-111. 10.1097/SHK.0b013e3180310f3a.CrossRefPubMed
48.
Vadasz I, Morty RE, Kohstall MG, Olschewski A, Grimminger F, Seeger W, Ghofrani HA: Oleic acid inhibits alveolar fluid reabsorption: a role in acute respiratory distress syndrome?. Am J Respir Crit Care Med. 2005, 171: 469-479. 10.1164/rccm.200407-954OC.CrossRefPubMed
49.
Richardson MA, Gupta A, O'Brien LA, Berg DT, Gerlitz B, Syed S, Sharma GR, Cramer MS, Heuer JG, Galbreath EJ, Grinnell BW: Treatment of sepsis-induced acquired protein C deficiency reverses Angiotensin-converting enzyme-2 inhibition and decreases pulmonary inflammatory response. J Pharmacol Exp Ther. 2008, 325: 17-26. 10.1124/jpet.107.130609.CrossRefPubMed
Metadata
Title
Recombinant human activated protein C ameliorates oleic acid-induced lung injury in awake sheep
Authors
Kristine Waerhaug
Mikhail Y Kirov
Vsevolod V Kuzkov
Vladimir N Kuklin
Lars J Bjertnaes
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Critical Care / Issue 6/2008
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc7128

Other articles of this Issue 6/2008

Critical Care 6/2008 Go to the issue

Review

Clinical review: Critical care management of spontaneous intracerebral hemorrhage

Commentary

The severity of sepsis: yet another factor influencing glycemic control

Research

Correlation between the AKI classification and outcome

Commentary

Pressure support ventilation attenuates ventilator-induced protein modifications in the diaphragm

Research

A prospective trial of elective extubation in brain injured patients meeting extubation criteria for ventilatory support: a feasibility study

Research

Incidence, organ dysfunction and mortality in severe sepsis: a Spanish multicentre study